New partnership between AMYPAD and ADDI powers global open access to Alzheimer’s disease imaging data

A common sign of Alzheimer’s disease are deposits of a protein called beta amyloid. The AMYPAD project studies the value of using an imaging technique called positron emission tomography (PET) to scan people’s brains for these beta amyloid deposits. AMYPAD carries out beta-amyloid PET imaging on a large number of people who are suspected to be in the early stages of Alzheimer’s disease. The goal is to determine the clinical added value of PET imaging in diagnosis and patient monitoring.

The AMYPAD consortium is pleased to announce its collaboration with the Alzheimer’s Disease Data Initiative (ADDI), a medical research organisation dedicated to fundamentally transforming Alzheimer’s disease (AD) research, accelerating progress towards new treatments and cures for AD and related dementias. This five-year partnership aims to share the data generated by the AMYPAD Prognostic and Natural History Study (PNHS) beyond the project duration in the ADDI platform. The AD Workbench is an open, global and free cloud-based platform for scientists to accelerate discoveries and innovations for AD and related dementias.

The first internal data-release of the AMYPAD PNHS study has been made in November 2021. Data from the multiple data sources have been integrated using the Aridhia Workspaces infrastructure, which has now been set-up within ADDI. The first data, together with the metadata describing the dataset, are now accessible through the AD Workbench for all members of the AMYPAD consortium. Further releases will be made periodically over 2022. Data access for researchers outside AMYPAD will be granted in the future through the AD Workbench FAIR metadata catalogue.

ADDI represents an excellent opportunity for AMYPAD to collaboratively mine its treasures in the AD Workbench. This collaboration will be extremely fruitful for AMYPAD in terms of its long-term sustainability plans.

This article has been originally posted on: